WAVE LIFE SCIENCES LTD. (WVE) Operating Margin
- Operating margin · 12 months: Value -333.36%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -333.36% | Operating income / revenue. Period ending 2026-06-30. $-217.92M ÷ $65.37M × 100 ≈ -333.36% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -217.92M USD | Operating Income (Loss) |
| Revenue | 65.37M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 197.42M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-217.92M | $65.37M | (m) | $197.42M | (m) | -333.36% |
| 2026-03-31 | $-196.88M | $71.80M | (m) | $189.60M | (m) | -274.21% |
| 2025-12-31 | $-215.38M | $42.73M | (m) | $182.78M | (m) | -504.09% |
| 2025-09-30 | $-135.95M | (m) | (m) | $174.61M | (m) | (m) |
| 2025-06-30 | $-143.51M | $93.95M | (m) | $169.93M | (m) | -152.76% |
| 2025-03-31 | $-125.75M | $104.94M | (m) | $166.86M | (m) | -119.83% |
| 2024-12-31 | $-110.40M | $108.30M | (m) | $159.68M | (m) | -101.94% |
| 2024-09-30 | $-152.05M | (m) | (m) | $149.11M | (m) | (m) |
| 2024-06-30 | $-83.69M | $110.50M | (m) | $139.56M | (m) | -75.74% |
| 2024-03-31 | $-72.17M | $112.91M | (m) | $132.48M | (m) | -63.92% |
| 2023-12-31 | $-68.00M | $113.31M | (m) | $130.01M | (m) | -60.01% |
| 2023-09-30 | $-92.88M | $85.49M | (m) | $127.01M | (m) | -108.64% |
| 2023-06-30 | $-136.22M | $36.56M | (m) | $122.95M | (m) | -372.60% |
| 2023-03-31 | $-154.91M | $14.83M | (m) | $119.36M | (m) | -1044.72% |
| 2022-12-31 | $-162.72M | $3.65M | (m) | $115.86M | (m) | -4459.30% |
| 2022-09-30 | $-155.27M | $4.17M | (m) | $110.54M | (m) | -3718.97% |
| 2022-06-30 | $-123.97M | $40.31M | (m) | $114.05M | (m) | -307.53% |
| 2022-03-31 | $-121.64M | $42.71M | (m) | $115.95M | (m) | -284.78% |
| 2021-12-31 | $-127.02M | $40.96M | (m) | $121.88M | (m) | -310.07% |
| 2021-09-30 | $-121.22M | $48.64M | (m) | $126.15M | (m) | -249.23% |
| 2021-06-30 | $-148.03M | $15.66M | (m) | $123.34M | (m) | -944.95% |
| 2021-03-31 | $-146.85M | (m) | (m) | $123.18M | (m) | (m) |
| 2020-12-31 | $-153.38M | $20.08M | (m) | $130.94M | (m) | -763.94% |
| 2020-09-30 | $-183.60M | $13.04M | (m) | $150.04M | (m) | -1408.17% |
| 2020-06-30 | $-203.36M | $12.52M | (m) | $166.35M | (m) | -1624.68% |
| 2020-03-31 | $-210.32M | $17.12M | (m) | $176.48M | (m) | -1228.66% |
| 2019-12-31 | $-208.32M | $15.98M | (m) | $175.43M | (m) | -1303.37% |
| 2019-09-30 | $-196.73M | $17.20M | (m) | $166.11M | (m) | -1143.56% |
| 2019-06-30 | $-180.78M | $18.77M | (m) | $154.40M | (m) | -963.29% |
| 2019-03-31 | $-171.74M | $16.02M | (m) | $145.34M | (m) | -1072.14% |
| 2018-12-31 | $-159.52M | $14.41M | (m) | $134.43M | (m) | -1106.72% |
| 2018-09-30 | $-141.93M | $11.70M | (m) | $119.99M | (m) | -1212.74% |
| 2018-06-30 | $-130.05M | $8.53M | (m) | $107.21M | (m) | -1525.49% |
| 2018-03-31 | $-118.15M | $4.74M | (m) | $93.77M | (m) | -2491.00% |
| 2017-12-31 | $-102.58M | $3.70M | (m) | $79.31M | (m) | -2769.44% |
| 2017-09-30 | $-90.50M | $2.70M | (m) | $67.94M | (m) | -3347.04% |
| 2017-06-30 | $-80.75M | $2.42M | (m) | $61.52M | (m) | -3336.57% |
| 2017-03-31 | $-67.29M | $2.16M | (m) | $50.82M | (m) | -3113.79% |
| 2016-12-31 | $-55.33M | $1.49M | (m) | $40.82M | (m) | -3725.72% |
| 2016-09-30 | $-44.04M | $809.00K | (m) | $30.29M | (m) | -5443.39% |
| 2016-06-30 | $-31.79M | $417.00K | (m) | $18.74M | (m) | -7624.46% |
| 2016-03-31 | $-23.79M | (m) | (m) | $12.19M | (m) | (m) |
| 2015-12-31 | $-19.30M | $152.00K | (m) | $9.06M | (m) | -12696.05% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-5.39M | (m) | (m) | $2.40M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-3.57M | (m) | (m) | $1.92M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |